BIND Therapeutics Inc
NASDAQ:
BIND
-
USD
OTHER
$0
-
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy BIND Therapeutics stock | $1.12
Learn how to easily invest in BIND Therapeutics stock.
BIND Therapeutics Inc is an other business based in the US. BIND Therapeutics shares (BIND) are listed on the NASDAQ and all prices are listed in US Dollars.
How to buy shares in BIND Therapeutics
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – BIND – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Our top pick for
Building a portfolio
Our top pick for
Social investors
Our top pick for
Beginners
BIND Therapeutics stock price (NASDAQ: BIND)
Use our graph to track the performance of BIND stocks over time.BIND Therapeutics shares at a glance
Information last updated 2020-08-13.
| Latest market close | $1.12 |
|---|---|
| 52-week range | $1.02 - $1.12 |
| 50-day moving average | $0.00 |
| Wall St. target price | $4.88 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | N/A |
Buy BIND Therapeutics shares from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy BIND Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
BIND Therapeutics price performance over time
Historical closes compared with the close of $1.12 from 2021-05-26
| 1 week (2021-07-22) | N/A |
|---|---|
| 1 month (2021-06-28) | N/A |
| 3 months (2021-04-30) | 2.75% |
| 6 months (2021-01-29) | N/A |
| 1 year (2020-07-29) | N/A |
|---|---|
| 2 years (2019-07-29) | N/A |
| 3 years (2018-07-29) | N/A |
| 5 years (2016-07-29) | N/A |
BIND Therapeutics financials
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | 0% |
| Return on equity TTM | 0% |
| Profit margin | 0% |
| Book value | N/A |
| Market capitalisation | $0 |
TTM: trailing 12 months
BIND Therapeutics share dividends
We're not expecting BIND Therapeutics to pay a dividend over the next 12 months.
BIND Therapeutics overview
BIND Therapeutics, Inc. is a clinical-stage nanomedicine platform company developing Accurins, its targeted and programmable therapeutics. Accurins are designed with specified physical and chemical characteristics to target specific cells or tissues and concentrate a therapeutic payload at the site of disease to enhance efficacy while minimizing adverse effects on healthy tissues. Its drug candidate, BIND-014, is in Phase II clinical trials for non-small cell lung cancer, or NSCLC, and metastatic castrate-resistant prostate cancer (mCRPC). .
BIND Therapeutics in the news
Frequently asked questions
When does the fiscal year end for BIND Therapeutics?BIND Therapeutics's fiscal year ends in December.
More guides on Finder
-
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
-
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
-
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
-
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
-
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
-
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
-
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
-
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
-
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
-
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert